Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Journal of the Brazilian Chemical Society (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532018000300615 |
Resumo: | Acute lymphoblastic leukemia (ALL) is a fatal disorder in most cases and is the most common cancer in young patients. ALL features an uncontrolled proliferation and maturation arrest of lymphoid progenitor cells (lymphoblast) in the bone marrow. An increase of reactive species production occurs in ALL with an involvement of oxidative stress (OS) and cellular damage. However, there is a lack of information about variations in young patients. The biomarker widely used to measure the OS is the main product of lipid peroxidation, the malondialdehyde (MDA). This biomarker, when evaluated by a chromatographic method and the data analyzed by multivariate analysis with other biochemical parameters of ALL patient charts, shows the distinction of healthy and ALL patients, and a great correlation with the risk of disease. |
id |
SBQ-2_07104d751daf66e2a056024f06688f71 |
---|---|
oai_identifier_str |
oai:scielo:S0103-50532018000300615 |
network_acronym_str |
SBQ-2 |
network_name_str |
Journal of the Brazilian Chemical Society (Online) |
repository_id_str |
|
spelling |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young PatientsmalondialdehydeHPLCprincipal components analysisprognosisAcute lymphoblastic leukemia (ALL) is a fatal disorder in most cases and is the most common cancer in young patients. ALL features an uncontrolled proliferation and maturation arrest of lymphoid progenitor cells (lymphoblast) in the bone marrow. An increase of reactive species production occurs in ALL with an involvement of oxidative stress (OS) and cellular damage. However, there is a lack of information about variations in young patients. The biomarker widely used to measure the OS is the main product of lipid peroxidation, the malondialdehyde (MDA). This biomarker, when evaluated by a chromatographic method and the data analyzed by multivariate analysis with other biochemical parameters of ALL patient charts, shows the distinction of healthy and ALL patients, and a great correlation with the risk of disease.Sociedade Brasileira de Química2018-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532018000300615Journal of the Brazilian Chemical Society v.29 n.3 2018reponame:Journal of the Brazilian Chemical Society (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.21577/0103-5053.20170175info:eu-repo/semantics/openAccessAlmeida,Mariana B.Carrilho,EmanuelNixdorf,Suzana L.eng2018-02-28T00:00:00Zoai:scielo:S0103-50532018000300615Revistahttp://jbcs.sbq.org.brONGhttps://old.scielo.br/oai/scielo-oai.php||office@jbcs.sbq.org.br1678-47900103-5053opendoar:2018-02-28T00:00Journal of the Brazilian Chemical Society (Online) - Sociedade Brasileira de Química (SBQ)false |
dc.title.none.fl_str_mv |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
title |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
spellingShingle |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients Almeida,Mariana B. malondialdehyde HPLC principal components analysis prognosis |
title_short |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
title_full |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
title_fullStr |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
title_full_unstemmed |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
title_sort |
Evaluation of Oxidative Stress in Patients with Acute Lymphoblastic Leukemia: Experimental Evidence of the Efficacy of MDA as Cancer Biomarker in Young Patients |
author |
Almeida,Mariana B. |
author_facet |
Almeida,Mariana B. Carrilho,Emanuel Nixdorf,Suzana L. |
author_role |
author |
author2 |
Carrilho,Emanuel Nixdorf,Suzana L. |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Almeida,Mariana B. Carrilho,Emanuel Nixdorf,Suzana L. |
dc.subject.por.fl_str_mv |
malondialdehyde HPLC principal components analysis prognosis |
topic |
malondialdehyde HPLC principal components analysis prognosis |
description |
Acute lymphoblastic leukemia (ALL) is a fatal disorder in most cases and is the most common cancer in young patients. ALL features an uncontrolled proliferation and maturation arrest of lymphoid progenitor cells (lymphoblast) in the bone marrow. An increase of reactive species production occurs in ALL with an involvement of oxidative stress (OS) and cellular damage. However, there is a lack of information about variations in young patients. The biomarker widely used to measure the OS is the main product of lipid peroxidation, the malondialdehyde (MDA). This biomarker, when evaluated by a chromatographic method and the data analyzed by multivariate analysis with other biochemical parameters of ALL patient charts, shows the distinction of healthy and ALL patients, and a great correlation with the risk of disease. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532018000300615 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532018000300615 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.21577/0103-5053.20170175 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
dc.source.none.fl_str_mv |
Journal of the Brazilian Chemical Society v.29 n.3 2018 reponame:Journal of the Brazilian Chemical Society (Online) instname:Sociedade Brasileira de Química (SBQ) instacron:SBQ |
instname_str |
Sociedade Brasileira de Química (SBQ) |
instacron_str |
SBQ |
institution |
SBQ |
reponame_str |
Journal of the Brazilian Chemical Society (Online) |
collection |
Journal of the Brazilian Chemical Society (Online) |
repository.name.fl_str_mv |
Journal of the Brazilian Chemical Society (Online) - Sociedade Brasileira de Química (SBQ) |
repository.mail.fl_str_mv |
||office@jbcs.sbq.org.br |
_version_ |
1750318180458299392 |